WEST BEND, Wis., April 3, 2008 /PRNewswire-FirstCall/ -- Mach One Corporation, http://www.machonecorp.com, (Pink Sheets: MNCN) announces that the final tests prior to large scale manufacturing of its ImmunoGam(TM) colostrum replacement product were completed last week.
"A highly qualified scientist from BioQual spent a week with us in our Belgium, Wisconsin facility completing a technology transfer and memorializing the protocols for manufacture of our flagship product ImmunoGam(TM)" stated Monte Tobin, President of Mach One. "The BioQual scientist couldn't believe the progress we have made in taking their original concept of colostrum replacement for the equine industry and adapting it through our own science to the dairy industry with ImmunoGam(TM). These newly designed protocols should revolutionize the colostrum replacement industry and in keeping with our corporate philosophy we will be 'building a better herd, one calf at a time(TM)'."
"ImmunoGam (TM) is a product that could be used for the nine million dairy calves born each year," continued Tobin, "This replacement product can be used as a time saving management tool for large dairies that have as many as 15 to 50 calves being born each day throughout a year. We see this as a great opportunity to strengthen the health of dairy cattle as a whole and to allow the dairyman to see full yields from his herd. Production in bulk should start within the next 10 days."
About Mach One Corporation
Through its wholly-owned subsidiary VDx, Inc. (http://www.vdxinc.com), the company will manufacture and sell Immunogam (TM), a colostrums replacement, supplement and prophylactic, in sterile powder form, which can be administered orally or intravenously. VDx is also further developing a proprietary procedure to allow for large scale manufacturing of colostral replacement products for market that includes an added ingredient for elimination of mastitis and Johnnes disease.
The IgG replacement market is estimated at 1.1 billion dollars per year.
Safe Harbor Statement
This press release contains forward-looking information. Readers are cautioned not to place undue reliance on any such forward-looking statements, each of which speaks only as of the date made. Such statements are subject to certain risks and uncertainties which are disclosed in the Company's SEC reports. These risks and uncertainties could cause actual results to differ materially from those currently anticipated or projected.
|SOURCE Mach One Corporation|
Copyright©2008 PR Newswire.
All rights reserved